Advances in Therapy

, Volume 27, Issue 2, pp 105–117 | Cite as

Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia

  • Stefan Krivoshiev
  • Volker Wizemann
  • Stanisław Czekalski
  • Adalbert Schiller
  • Steva Plješa
  • Michael Wolf-Pflugmann
  • Marianne Siebert-Weigel
  • Rossen Koytchev
  • Angelika Bronn
  • Epoetin Zeta Study Group
Original Research

Abstract

Introduction

The primary objective of the trial was to prove the therapeutic equivalence of epoetin zeta to epoetin alfa when administered subcutaneously for maintaining target hemoglobin (Hb) in patients with renal anemia on chronic hemodialysis. Additional information was provided on the safety and tolerability of epoetin zeta with particular focus on the formation of anti-erythropoietin antibodies.

Methods

A total of 462 patients were randomized to either epoetin zeta or alfa for 28 weeks after an open period of dose adjustment of 12–16 weeks with only epoetin zeta. The aim of treatment was to maintain Hb between 10.0–12.0 g/dL with constant epoetin dosage. Primary endpoints were the mean Hb level and the mean weekly epoetin dosage during the last 4 weeks of treatment. Safety endpoints were the occurrence of anti-erythropoietin antibodies, incidence of Hb levels above 13 g/dL, ratings of tolerability, and adverse events (AEs).

Results

The mean Hb level (±SD) during the last 4 weeks of treatment was 10.94±0.84 g/dL (epoetin zeta) and 11.02±0.94 g/dL (epoetin alfa). The 95% confidence interval (CI) (″C0.28 g/dL to 0.12 g/dL) was entirely within the predefined equivalence range (±0.5 g/dL). The mean weekly epoetin dosage per body weight over the last 4 weeks of treatment was 97.0±94.3 IU/kg/week (epoetin zeta) and 86.0±78.0 IU/kg/week (epoetin alfa). The 95% CI (″C8.06 IU/kg/week to 29.96 IU/kg/week) was also within the predefined equivalence range of ±45 IU/kg/week. The most common AEs were infections and infestations (15.1% of patients on epoetin zeta and 14.8% of patients on epoetin alfa). None of the patients developed antierythropoietin antibodies.

Conclusions

Epoetin zeta, administered subcutaneously, is equivalent to epoetin alfa in respect of its clinical efficacy. The safety profile of both products is similar: no unexpected AEs were observed, no patients developed anti-erythropoietin antibodies, and both epoetin preparations were well tolerated.

Keywords

efficacy epoetin zeta equivalence erythropoietin maintenance treatment safety 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant. 1999;14:22–28.CrossRefPubMedGoogle Scholar
  2. 2.
    Erypo / Erypo FS [Summary of product characteristics]. Neuss, Germany: Janssen-Cilag GmbH; 2002.Google Scholar
  3. 3.
    Levin A. Identification of patients and risk factors in chronic kidney disease — evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant. 2001;7:57–60.Google Scholar
  4. 4.
    Macdougall IC. Treatment of renal anemia with recombinant human erythropoietin. Curr Opin Nephrol Hypertens. 1992;1:210–219.CrossRefPubMedGoogle Scholar
  5. 5.
    European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products (CHMP/437/04). Available at: www.ema.europa. eu/pdfs/human/biosimilar/043704en.pdf. Accessed March 11, 2010.Google Scholar
  6. 6.
    Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008;25:1215–1228.CrossRefPubMedGoogle Scholar
  7. 7.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, The Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anemia treatment. Curr Med Res Opin. 2008;24:625–637.CrossRefPubMedGoogle Scholar
  8. 8.
    Krivoshiev S, Todorov V, Manitius J, et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anemia. Curr Med Res Opin. 2008;24:1407–1415.CrossRefPubMedGoogle Scholar
  9. 9.
    European Medicines Agency Committee for Medicinal Products for Human Use. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues: guidance on similar medicinal products containing recombinant erythropoietins (CHMP/94526/05). Available at: www.emea.europa.eu/htms/human/ humanguidelines/nonclinical.htm. Accessed March 11, 2010.Google Scholar
  10. 10.
    NeoRecormon [Summary of product characteristics]. Welwyn Garden City, UK: Roche Registration Limited; 2002.Google Scholar
  11. 11.
    Eprex [product monograph]. Toronto, Canada: Janssen-Ortho Inc.; 2006.Google Scholar
  12. 12.
    Casadevall N, Cournoyer D, Marsh J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol. 2004;73:389–396.CrossRefPubMedGoogle Scholar
  13. 13.
    ICH Topic E 6 R1. Guideline for good clinical practice. Step 5, consolidated guideline from 01.05.1996. Note for guidance on good clinical practice (CPMP/ICH/135/95). January 1997. Available at: www.ema.europa.eu/pdfs/human/ich/013595en.pdf. Accessed March 11, 2010.Google Scholar
  14. 14.
    European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 1999;14:5–36.Google Scholar
  15. 15.
    European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on immunogenicity assessment of biotechnologyderived therapeutic proteins (CHMP/14327/06). Available at: www.ema.europa.eu/htms/human/humanguidelines/multidiscipline.htm. Accessed March 11, 2010.Google Scholar
  16. 16.
    Tacey R, Greyway A, Smiell J, et al. The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. J Immunol Methods. 2003;283:317–329.CrossRefPubMedGoogle Scholar
  17. 17.
    Food and Drug Administraion. Draft Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: US FDA; 1999.Google Scholar
  18. 18.
    ICH Topic E 9. Statistical principles for clinical trials. Note for guidance on statistical principles for clinical trials (CPMP/ICH/363/96). Available at: www.ema.europa.eu/pdfs/human/ich/036396en.pdf. Accessed March 11, 2010.Google Scholar
  19. 19.
    Casadevall N, Eckardt K-U, Rossert J. Epoetininduced autoimmune pure red cell aplasia. J Am Soc Nephrol. 2005;16:67–69.CrossRefGoogle Scholar

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  • Stefan Krivoshiev
    • 1
  • Volker Wizemann
    • 2
  • Stanisław Czekalski
    • 3
  • Adalbert Schiller
    • 4
  • Steva Plješa
    • 5
  • Michael Wolf-Pflugmann
    • 6
  • Marianne Siebert-Weigel
    • 6
  • Rossen Koytchev
    • 7
  • Angelika Bronn
    • 7
  • Epoetin Zeta Study Group
  1. 1.Multidisciplinary Hospital for Active Treatment “Queen Giovanna” Ltd.SofiaBulgaria
  2. 2.Georg-Haas-DialysezentrumGießenGermany
  3. 3.Department of Nephrology, Transplantation and Internal DiseasesUniversity of Medical SciencesPoznanPoland
  4. 4.Emergency Clinical HospitalTimisoaraRomania
  5. 5.Clinical Hospital ZemunBelgradeSerbia
  6. 6.STADA R&D GmbHBad VilbelGermany
  7. 7.CCDRD AGNeuenhagenGermany

Personalised recommendations